NCT05212623 - A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 26, 2021

Primary Completion Date

January 17, 2022

Study Completion Date

June 16, 2022

Conditions

Influenza

Interventions

BIOLOGICAL

quadrivalent influenza split vaccine

This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection

BIOLOGICAL

quadrivalent influenza split vaccine

This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection

BIOLOGICAL

Influenza virus split vaccine

This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection

BIOLOGICAL

Influenza virus split vaccine

This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.

Trial Locations (1)

210009

Jiangsu Province Centers for Disease Control and Prevention, Nanjing